Platinum Compound-Related Ototoxicity in Children

Bertolini, Patrizia; Lassalle, Mathilde; Mercier, Guilaine; Raquin, Marie Anne; Izzi, Giancarlo; Corradini, Nadège; Hartmann, Olivier

doi:10.1097/01.mph.0000141348.62532.73

Cited by 267 publications

(86 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CDDP is one of the most effective and widely used cytotoxic agents for the treatment of adult and pediatric malignancies [1,2,3,4,5,6]. Ototoxicity, neurotoxicity and nephrotoxicity are major dose-limiting side effects of CDDP.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Effect of Acetyl <i>L</i>-Carnitine on Experimental Cisplatin Ototoxicity and Neurotoxicity

Güneş

Kırkım²,

Kolatan³

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

Introduction: Cisplatin (CDDP) is an effective and widely used chemotherapeutic agent for pediatric tumors, and ototoxicity is one of the dose-limiting side effects. Objective: It was the aim of our study to investigate the effect of acetyl L-carnitine (ALCAR) on experimental CDDP ototoxicity by audiologic tests, histomorphologic, immunohistochemical and ultrastructural examinations and to investigate the apoptotic pathways. Materials and Methods: Wistar albino rats (n = 28) were studied. Baseline audiological tests were performed in 4 groups: group 1, control; group 2, ALCAR; group 3, CDDP; group 4, CDDP + ALCAR-administered rats. Control audiological tests were performed on the 3rd day, and then the rats were sacrificed. Ear and brain specimens were examined by transmission electron microscopy, and caspase 3, 8 and 9 activities were investigated. Results: The CDDP-administered rats showed significant auditory brainstem response threshold shifts using all stimuli (clicks, 6-kHz and 8-kHz tone burst) compared with the control groups. The CDDP + ALCAR-administered rats showed significant auditory brainstem response threshold shifts by only click stimuli compared with the control groups. In the brain, spiral ganglion and organ of Corti, ultrastructural damage was prominent in group 3; the number of TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling)-positive cells and caspase 3, 8 and 9 immunostaining cells was significantly high in group 3. Conclusion: ALCAR improves CDDP-induced auditory impairment, and also antioxidative and antiapoptotic properties of ALCAR on CDDP ototoxicity were supported by the findings.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Ototoxicity, neurotoxicity and nephrotoxicity are major dose-limiting side effects of CDDP. CDDP-induced ototoxicity is characterized by bilateral, usually permanent, high-frequency sensorineural hearing loss that can progress to the lower frequencies [2,3,4,5,6]. There is an individual susceptibility to CDDP ototoxicity.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Effect of Acetyl <i>L</i>-Carnitine on Experimental Cisplatin Ototoxicity and Neurotoxicity

Güneş

Kırkım²,

Kolatan³

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…48;49 Ototoxicity following these exposures first affects higher frequencies (>4 KHz) and with continued exposure can progress to involve lower (speech) frequencies. 50 Hearing loss also can continue to worsen after completion of therapy and be accompanied by tinnitus and vertigo. 50 Radiation alone with cumulative cochlear dose ≥30 Gy (inclusive of any TBI or cranial radiation) also is associated with sensorineural hearing loss, which may develop and/or progress years after exposure.…”

Section: Sensorymentioning

confidence: 99%

“…50 Hearing loss also can continue to worsen after completion of therapy and be accompanied by tinnitus and vertigo. 50 Radiation alone with cumulative cochlear dose ≥30 Gy (inclusive of any TBI or cranial radiation) also is associated with sensorineural hearing loss, which may develop and/or progress years after exposure. 48;51 Additionally, radiotherapy also can result in conductive hearing loss, tympanosclerosis, otosclerosis, and Eustachian tube dysfunction.…”

Section: Sensorymentioning

confidence: 99%

Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report

Chow

Anderson

Baker

et al. 2016

Biology of Blood and Marrow Transplantation

174

152

View full text Add to dashboard Cite

Hematopoietic cell transplantation (HCT) is an important curative treatment for children with high-risk hematologic malignancies and solid tumors, and increasingly, non-malignant diseases. Given improvements in care, there is a growing number of long-term survivors of pediatric HCT. Compared with non-transplanted childhood cancer survivors, HCT survivors have been shown to have a substantially increased burden of serious chronic conditions and impairments involving virtually every organ system and overall quality of life. This likely reflects the joint contributions of pre-transplant treatment exposures and organ dysfunction, the transplant conditioning regimen, and any post-transplant graft versus host disease (GVHD). In response, the Children’s Oncology Group (COG) has created Long-Term Follow-Up Guidelines (www.survivorshipguidelines.org) for survivors of childhood, adolescent, and young adult cancer, including those treated with HCT. Guidelines taskforces, consisting of HCT specialists, other pediatric oncologists, radiation oncologists, organ-specific subspecialists, nurses, social workers, other healthcare professionals, and patient advocates have systematically reviewed the literature with regards to late effects after childhood cancer and HCT since 2002, with the most recent review completed in 2013. For the most recent review cycle, over 800 articles from the medical literature relevant to childhood cancer and HCT survivorship were reviewed, including 586 original research articles. Provided here-in is an organ system-based overview that emphasizes the most relevant COG recommendations (with accompanying evidence grade) for the long-term follow-up care of childhood HCT survivors (regardless of current age) based on a rigorous review of the available evidence. These recommendations cover both autologous and allogeneic HCT survivors, those transplanted for non-malignant diseases, and those with a history of chronic GVHD.

show abstract

“…In contrast, Stern and Bunin [11] found that ototoxic complications from carboplatin chemotherapy were rare and mild in severity. Other studies have also reported a lack of ototoxic side effects in children receiving carboplatin [12,13]. Factors that may potentiate carboplatin ototoxicity include prior exposure to cisplatin or other ototoxic medications and high dosages of carboplatin [7,10,14].…”

Section: Introductionmentioning

confidence: 99%

Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma

Bhagat

Bass

White

et al. 2010

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

Objective Carboplatin is a common chemotherapy agent with potential ototoxic side effects that is used to treat a variety of pediatric cancers, including retinoblastoma. Retinoblastoma is a malignant tumor of the retina that is usually diagnosed in young children. Distortion-product otoacoustic emission tests offer an effective method of monitoring for ototoxicity in young children. This study was designed to compare measurements of distortion-product otoacoustic emissions obtained before and after several courses of carboplatin chemotherapy in order to examine if (a) mean distortion-product otoacoustic emission levels were significantly different; and (b) if criterion reductions in distortion-product otoacoustic emission levels were observed in individual children. Methods A prospective repeated measures study. Ten children with a median age of 7.6 months (range, 3–72 months) diagnosed with unilateral or bilateral retinoblastoma were examined. Distortion-product otoacoustic emissions were acquired from both ears of the children with 65/55 dB SPL primary tones (f2= 793–7996 Hz) and a frequency resolution of 3 points/octave. Distortion-product otoacoustic emission levels in dB SPL were measured before chemotherapy treatment (baseline measurement) and after 3–4 courses of chemotherapy (interim measurement). Comparisons were made between baseline and interim distortion-product otoacoustic emission levels (collapsed across ears). Evidence of ototoxicity was based on criterion reductions (≥ 6 dB) in distortion-product otoacoustic emission levels. Results Significant differences between baseline and interim mean distortion-product otoacoustic emission levels were only observed at f2=7996 Hz. Four children exhibited criterion reductions in distortion-product otoacoustic emission levels. Conclusions Mean distortion-product otoacoustic emission levels at most frequencies were not changed following 3–4 courses of carboplatin chemotherapy in children with retinoblastoma. However, on an individual basis, children receiving higher doses of carboplatin exhibited criterion reductions in distortion-product otoacoustic emission level at several frequencies. These findings suggest that higher doses of carboplatin affect outer hair cell function, and distortion-product otoacoustic emission tests can provide useful information when monitoring children at risk of developing carboplatin ototoxicity.

show abstract

Platinum Compound-Related Ototoxicity in Children

Cited by 267 publications

References 42 publications

Evaluation of the Effect of Acetyl <i>L</i>-Carnitine on Experimental Cisplatin Ototoxicity and Neurotoxicity

Evaluation of the Effect of Acetyl <i>L</i>-Carnitine on Experimental Cisplatin Ototoxicity and Neurotoxicity

Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report

Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma

Contact Info

Product

Resources

About